JP2019534865A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534865A5 JP2019534865A5 JP2019515887A JP2019515887A JP2019534865A5 JP 2019534865 A5 JP2019534865 A5 JP 2019534865A5 JP 2019515887 A JP2019515887 A JP 2019515887A JP 2019515887 A JP2019515887 A JP 2019515887A JP 2019534865 A5 JP2019534865 A5 JP 2019534865A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- aryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 79
- 150000003839 salts Chemical class 0.000 claims description 48
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- -1 substituted Chemical class 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 230000005907 cancer growth Effects 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 0 *c(ccc1nc(*)c2)cc1c2ICI* Chemical compound *c(ccc1nc(*)c2)cc1c2ICI* 0.000 description 107
- ITQTTZVARXURQS-UHFFFAOYSA-N Cc1cccnc1 Chemical compound Cc1cccnc1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 10
- PHZREHARUPHHCU-UHFFFAOYSA-N Cc(c(O)c1O)ccc1O Chemical compound Cc(c(O)c1O)ccc1O PHZREHARUPHHCU-UHFFFAOYSA-N 0.000 description 8
- STRWKFUEXQHMFW-UHFFFAOYSA-N Cc(cc1)ccc1N1CCCC1 Chemical compound Cc(cc1)ccc1N1CCCC1 STRWKFUEXQHMFW-UHFFFAOYSA-N 0.000 description 6
- RLADTPQRCGVXDS-UHFFFAOYSA-N Cc1ccc(CCN2CCCC2)cc1 Chemical compound Cc1ccc(CCN2CCCC2)cc1 RLADTPQRCGVXDS-UHFFFAOYSA-N 0.000 description 6
- QWHFEMQVSQIMJL-UHFFFAOYSA-N CCCC(c1ccc(CN2CCCC2)cc1)=O Chemical compound CCCC(c1ccc(CN2CCCC2)cc1)=O QWHFEMQVSQIMJL-UHFFFAOYSA-N 0.000 description 4
- RXVGQIBJNXFOOI-UHFFFAOYSA-N CCCN1CCN(C)CC1 Chemical compound CCCN1CCN(C)CC1 RXVGQIBJNXFOOI-UHFFFAOYSA-N 0.000 description 4
- GYVGXEWAOAAJEU-UHFFFAOYSA-N Cc(cc1)ccc1N(C)C Chemical compound Cc(cc1)ccc1N(C)C GYVGXEWAOAAJEU-UHFFFAOYSA-N 0.000 description 4
- GYPMBQZAVBFUIZ-UHFFFAOYSA-N Cc(cc1OC)ccc1OC Chemical compound Cc(cc1OC)ccc1OC GYPMBQZAVBFUIZ-UHFFFAOYSA-N 0.000 description 4
- ONQBOTKLCMXPOF-UHFFFAOYSA-N CCN1CCCC1 Chemical compound CCN1CCCC1 ONQBOTKLCMXPOF-UHFFFAOYSA-N 0.000 description 3
- OPBDSRFLAMJZFP-UHFFFAOYSA-N C(C1)C1c1cnccc1 Chemical compound C(C1)C1c1cnccc1 OPBDSRFLAMJZFP-UHFFFAOYSA-N 0.000 description 2
- DEGXTCKEZCCZOP-UHFFFAOYSA-N CC(C)Cc1cnccc1 Chemical compound CC(C)Cc1cnccc1 DEGXTCKEZCCZOP-UHFFFAOYSA-N 0.000 description 2
- QWXBVRRUKZHDQL-UHFFFAOYSA-N CC(C)c(cc1)ccc1C(NC(C)C)=O Chemical compound CC(C)c(cc1)ccc1C(NC(C)C)=O QWXBVRRUKZHDQL-UHFFFAOYSA-N 0.000 description 2
- YTZRDHFUHIYZOF-UHFFFAOYSA-N CC(C1)C(c2ccc(C)cc2)=CC=C1C(O)=O Chemical compound CC(C1)C(c2ccc(C)cc2)=CC=C1C(O)=O YTZRDHFUHIYZOF-UHFFFAOYSA-N 0.000 description 2
- ORFVOGXKZGVSAZ-UHFFFAOYSA-N CC(CC1)CCN1C(CCC=C)=O Chemical compound CC(CC1)CCN1C(CCC=C)=O ORFVOGXKZGVSAZ-UHFFFAOYSA-N 0.000 description 2
- DWCFBWPLRGQFLN-UHFFFAOYSA-N CC(c1ccccc1)(F)F Chemical compound CC(c1ccccc1)(F)F DWCFBWPLRGQFLN-UHFFFAOYSA-N 0.000 description 2
- HEIAAGNBEHLVCZ-UHFFFAOYSA-N CCCc(cc1)ccc1C#N Chemical compound CCCc(cc1)ccc1C#N HEIAAGNBEHLVCZ-UHFFFAOYSA-N 0.000 description 2
- YXLFQKUIZVSIEP-UHFFFAOYSA-N CCCc(cc1OC)ccc1OC Chemical compound CCCc(cc1OC)ccc1OC YXLFQKUIZVSIEP-UHFFFAOYSA-N 0.000 description 2
- XLJCEWXIEVXDCP-UHFFFAOYSA-N CCCc1ccc(C(C)(C)C)cc1 Chemical compound CCCc1ccc(C(C)(C)C)cc1 XLJCEWXIEVXDCP-UHFFFAOYSA-N 0.000 description 2
- DVWOVSRLFSASKK-UHFFFAOYSA-N CCCc1cccc(C(F)(F)F)c1 Chemical compound CCCc1cccc(C(F)(F)F)c1 DVWOVSRLFSASKK-UHFFFAOYSA-N 0.000 description 2
- NTAIOEZEVLVLLW-UHFFFAOYSA-N CCSCc1ccccc1 Chemical compound CCSCc1ccccc1 NTAIOEZEVLVLLW-UHFFFAOYSA-N 0.000 description 2
- NIUHFBSLQBRLDY-UHFFFAOYSA-N CCc1ccc(CCN2CCCC2)cc1 Chemical compound CCc1ccc(CCN2CCCC2)cc1 NIUHFBSLQBRLDY-UHFFFAOYSA-N 0.000 description 2
- MFEIKQPHQINPRI-UHFFFAOYSA-N CCc1cnccc1 Chemical compound CCc1cnccc1 MFEIKQPHQINPRI-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- BPHYZRNTQNPLFI-UHFFFAOYSA-N Cc(c(O)cc(O)c1)c1O Chemical compound Cc(c(O)cc(O)c1)c1O BPHYZRNTQNPLFI-UHFFFAOYSA-N 0.000 description 2
- ZGEAYXBIJAYBKA-UHFFFAOYSA-N Cc(cc(c(F)c1)F)c1F Chemical compound Cc(cc(c(F)c1)F)c1F ZGEAYXBIJAYBKA-UHFFFAOYSA-N 0.000 description 2
- NSUWJKRQGXBISO-UHFFFAOYSA-N Cc(cc1)ccc1-c(cc1)ccc1C(OC)=O Chemical compound Cc(cc1)ccc1-c(cc1)ccc1C(OC)=O NSUWJKRQGXBISO-UHFFFAOYSA-N 0.000 description 2
- ZBTMRBYMKUEVEU-UHFFFAOYSA-N Cc(cc1)ccc1Br Chemical compound Cc(cc1)ccc1Br ZBTMRBYMKUEVEU-UHFFFAOYSA-N 0.000 description 2
- LPNBBFKOUUSUDB-UHFFFAOYSA-N Cc(cc1)ccc1C(O)=O Chemical compound Cc(cc1)ccc1C(O)=O LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 2
- WRWPPGUCZBJXKX-UHFFFAOYSA-N Cc(cc1)ccc1F Chemical compound Cc(cc1)ccc1F WRWPPGUCZBJXKX-UHFFFAOYSA-N 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N Cc(cc1)ccc1O Chemical compound Cc(cc1)ccc1O IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- CHBXCQHBCCLICW-UHFFFAOYSA-N Cc(cc1)ccc1OCc1ccccc1 Chemical compound Cc(cc1)ccc1OCc1ccccc1 CHBXCQHBCCLICW-UHFFFAOYSA-N 0.000 description 2
- ZBCATMYQYDCTIZ-UHFFFAOYSA-N Cc(cc1O)ccc1O Chemical compound Cc(cc1O)ccc1O ZBCATMYQYDCTIZ-UHFFFAOYSA-N 0.000 description 2
- OSNMRWURXNWCGA-UHFFFAOYSA-N Cc(ccc(OC)c1)c1OC Chemical compound Cc(ccc(OC)c1)c1OC OSNMRWURXNWCGA-UHFFFAOYSA-N 0.000 description 2
- VQKFNUFAXTZWDK-UHFFFAOYSA-N Cc1ccc[o]1 Chemical compound Cc1ccc[o]1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 2
- KSYQGOYOIKQFNA-UHFFFAOYSA-N Cc1cccc(Cc2ccccc2)c1 Chemical compound Cc1cccc(Cc2ccccc2)c1 KSYQGOYOIKQFNA-UHFFFAOYSA-N 0.000 description 2
- TWGNOYAGHYUFFR-UHFFFAOYSA-N Cc1cncnc1 Chemical compound Cc1cncnc1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 description 2
- FSWRUYCICUXURT-UHFFFAOYSA-N Cc1nc(nccc2)c2cc1 Chemical compound Cc1nc(nccc2)c2cc1 FSWRUYCICUXURT-UHFFFAOYSA-N 0.000 description 2
- LXBGSDVWAMZHDD-UHFFFAOYSA-N Cc1ncc[nH]1 Chemical compound Cc1ncc[nH]1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 2
- LCRQUUZUHKDXKY-RVDMUPIBSA-N CC(C)/N=C/c(cc1)ccc1N1CCCC1 Chemical compound CC(C)/N=C/c(cc1)ccc1N1CCCC1 LCRQUUZUHKDXKY-RVDMUPIBSA-N 0.000 description 1
- DADIVWBUMHXXRQ-UHFFFAOYSA-N CC1=CCC(CCN2CCCC2)C=C1 Chemical compound CC1=CCC(CCN2CCCC2)C=C1 DADIVWBUMHXXRQ-UHFFFAOYSA-N 0.000 description 1
- NEBQMYHKOREVAL-UHFFFAOYSA-N CCc(cc1OC)ccc1OC Chemical compound CCc(cc1OC)ccc1OC NEBQMYHKOREVAL-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022148999A JP2022174272A (ja) | 2016-09-26 | 2022-09-20 | クロモボックスタンパク質阻害剤およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662399857P | 2016-09-26 | 2016-09-26 | |
| US62/399,857 | 2016-09-26 | ||
| PCT/US2017/053229 WO2018058029A1 (en) | 2016-09-26 | 2017-09-25 | Chromobox protein inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022148999A Division JP2022174272A (ja) | 2016-09-26 | 2022-09-20 | クロモボックスタンパク質阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534865A JP2019534865A (ja) | 2019-12-05 |
| JP2019534865A5 true JP2019534865A5 (https=) | 2020-11-12 |
| JP7203018B2 JP7203018B2 (ja) | 2023-01-12 |
Family
ID=61690673
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515887A Active JP7203018B2 (ja) | 2016-09-26 | 2017-09-25 | クロモボックスタンパク質阻害剤およびその使用 |
| JP2022148999A Pending JP2022174272A (ja) | 2016-09-26 | 2022-09-20 | クロモボックスタンパク質阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022148999A Pending JP2022174272A (ja) | 2016-09-26 | 2022-09-20 | クロモボックスタンパク質阻害剤およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12129248B2 (https=) |
| EP (2) | EP3515449B1 (https=) |
| JP (2) | JP7203018B2 (https=) |
| AU (1) | AU2017330443B2 (https=) |
| CA (1) | CA3034652A1 (https=) |
| WO (1) | WO2018058029A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10925875B2 (en) * | 2018-01-23 | 2021-02-23 | National Jewish Health | Methods of treating steroid resistant diseases and conditions |
| CA3134826A1 (en) * | 2019-03-28 | 2020-10-01 | Epizyme, Inc. | Quinoline derivatives and their use for the treatment of cancer |
| CN113336759B (zh) * | 2020-12-25 | 2022-12-06 | 中国药科大学 | 溴结构域蛋白4小分子抑制剂、其制备方法及应用 |
| WO2024089045A1 (en) * | 2022-10-24 | 2024-05-02 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Tasl mimicking molecules and applications thereof |
| WO2024108227A1 (en) * | 2022-11-18 | 2024-05-23 | The Regents Of The University Of Colorado, A Body Corporate | Cbx2 inhibitory compounds for treating high grade serous ovarian cancer |
| CN116354959B (zh) * | 2023-03-10 | 2024-04-19 | 石河子大学 | 一种N-N桥连噻唑单元的β-咔啉衍生物及其制备方法、应用 |
| CN116554123A (zh) * | 2023-04-27 | 2023-08-08 | 山东大学 | 六种噻唑酰腙类化合物在抗肿瘤药物中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US5645988A (en) * | 1991-05-08 | 1997-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of identifying drugs with selective effects against cancer cells |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| WO1998057931A2 (en) * | 1997-06-19 | 1998-12-23 | Sepracor Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| DK0999825T3 (da) | 1997-07-29 | 2004-02-09 | Alcon Lab Inc | Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater |
| US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| CA2534484A1 (en) | 2003-08-07 | 2005-02-17 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| JP2008517061A (ja) | 2004-10-20 | 2008-05-22 | コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー | 抗腫瘍剤としての化合物及びそれらの使用 |
| WO2006094237A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline dervatives as sirtuin modulators |
| US20070099970A1 (en) | 2005-08-19 | 2007-05-03 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain |
| JP5460054B2 (ja) | 2005-11-23 | 2014-04-02 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法 |
| WO2008063378A2 (en) * | 2006-11-01 | 2008-05-29 | Ventana Medical Systems, Inc. | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
| WO2008090327A1 (en) * | 2007-01-22 | 2008-07-31 | Betagenon Ab | New combination for use in the treatment of cancer |
| US8183236B2 (en) | 2007-04-12 | 2012-05-22 | University Of Southern California | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics |
| US20090118135A1 (en) * | 2007-06-08 | 2009-05-07 | The Burnham Institute | Methods and compounds for regulating apoptosis |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2242367A4 (en) | 2008-01-08 | 2012-07-04 | Univ Pennsylvania | Rel inhibitors and methods of use thereof |
| CN102099352B (zh) * | 2008-07-10 | 2014-02-26 | 一般社团法人创药分子Ip | 以喹啉甲酰胺衍生物为有效成分的stat3抑制剂 |
| US8563580B2 (en) | 2008-09-23 | 2013-10-22 | Georgetown University | Flavivirus inhibitors and methods for their use |
| US20110077250A1 (en) * | 2009-06-26 | 2011-03-31 | Ryder Sean | Compounds for modulating rna binding proteins and uses therefor |
| AU2011210567B2 (en) * | 2010-01-29 | 2015-04-16 | Dana-Farber Cancer Institute, Inc. | Small molecules for the modulation of MCL-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders |
| EP2635280A4 (en) | 2010-11-05 | 2014-05-28 | Univ Minnesota | CYTOSINDEAMINASE MODULATORS TO IMPROVE DNA TRANSFECTION |
| US9051305B2 (en) | 2011-03-08 | 2015-06-09 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| WO2013059944A1 (en) | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
| CA2861066C (en) | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
| US9261497B2 (en) | 2012-10-16 | 2016-02-16 | New York University | Method of treating cancer with modulators of SCFSkp2 |
| WO2014113467A1 (en) | 2013-01-15 | 2014-07-24 | Board Of Regents, The University Of Texas System | Stat3 inhibitor |
| AU2014233757B2 (en) | 2013-03-18 | 2017-12-21 | Genoscience Pharma | Quinolines derivatives as novel anticancer agents |
| KR20160030221A (ko) | 2013-07-10 | 2016-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
| WO2016004035A1 (en) | 2014-07-01 | 2016-01-07 | Icahn School Of Medicine At Mount Sinai | 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases |
| WO2016077632A2 (en) * | 2014-11-13 | 2016-05-19 | Buck Institute For Research On Aging | Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications |
-
2017
- 2017-09-25 WO PCT/US2017/053229 patent/WO2018058029A1/en not_active Ceased
- 2017-09-25 JP JP2019515887A patent/JP7203018B2/ja active Active
- 2017-09-25 US US16/335,951 patent/US12129248B2/en active Active
- 2017-09-25 AU AU2017330443A patent/AU2017330443B2/en active Active
- 2017-09-25 CA CA3034652A patent/CA3034652A1/en active Pending
- 2017-09-25 EP EP17854068.8A patent/EP3515449B1/en active Active
- 2017-09-25 EP EP23182319.6A patent/EP4275759B1/en active Active
-
2022
- 2022-09-20 JP JP2022148999A patent/JP2022174272A/ja active Pending
-
2024
- 2024-09-26 US US18/898,034 patent/US20250034126A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534865A5 (https=) | ||
| JP2012153722A5 (https=) | ||
| JP2019512478A5 (https=) | ||
| JP2008535902A5 (https=) | ||
| JP2020525429A5 (https=) | ||
| JP2013522292A5 (https=) | ||
| JP2017525730A5 (https=) | ||
| JP2017536344A5 (https=) | ||
| JP2016503414A5 (https=) | ||
| JP2017507175A5 (https=) | ||
| JP2015512943A5 (https=) | ||
| JP2019513734A5 (https=) | ||
| JP2016519062A5 (https=) | ||
| JP2017526662A5 (https=) | ||
| RU2015126856A (ru) | Дисульфидные маскированные пролекарственные композиции и способы | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| JP2010523670A5 (https=) | ||
| JP2016503799A5 (https=) | ||
| JP2016514719A5 (https=) | ||
| JP2017511321A5 (https=) | ||
| JP2006505543A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| JP2013544860A5 (https=) | ||
| JP2017524013A5 (https=) | ||
| JP2013502441A5 (https=) |